Other languages G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
4.44 ^USD	+7.51%		+15.03%	+45.57%

01/05	Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
01/05	Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib	01/05
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	28/02
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Top Midday Decliners	14/02
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	13/02
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	13/02
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	13/02
G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC	08/01
G1 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023	01/11
G1 Therapeutics' COSELA(R) (Trilaciclib) Recommends in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology	18/23/18
G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023	22/23/22
Insider Sell: G1 Therapeutics	11/23/11
EQRx, Inc. Provides Written Notice to G1 Therapeutics of its Termination of the Exclusive License Agreement	04/23/04
G1 Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/23/02
G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023	02/23/02
Cancer drugmakers rise as industry meet fuels investor interest	05/23/05
G1 THERAPEUTICS SHARES UP 6.8% AFTER CO REPORTS POSITIVE DATA FR…	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Other languages

Filters